<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;ff=20230727062803&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;ff=20230727062803&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 27 Jul 2023 10:28:04 +0000</lastbuilddate>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495284/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):469-471. doi: 10.1016/j.jacc.2023.05.012. Epub 2023 May 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495284/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495284</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.012>10.1016/j.jacc.2023.05.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495284</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Jakub Sroubek</dc:creator>
<dc:creator>Ramya Vajapey</dc:creator>
<dc:creator>Joseph J Sipko</dc:creator>
<dc:creator>Edward G Soltesz</dc:creator>
<dc:creator>Aaron J Weiss</dc:creator>
<dc:creator>Mandeep Bhargava</dc:creator>
<dc:creator>Ayman A Hussein</dc:creator>
<dc:creator>Mohamed Kanj</dc:creator>
<dc:creator>Walid I Saliba</dc:creator>
<dc:creator>Tyler L Taigen</dc:creator>
<dc:creator>Oussama M Wazni</dc:creator>
<dc:creator>Pasquale Santangeli</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation</dc:title>
<dc:identifier>pmid:37495284</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.012</dc:identifier>
</item>
<item>
<title>In-Person vs Virtual Interview Format for Fellowships in Cardiovascular Disease: A Nationwide Survey of Fellows-in-Training</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495283/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):465-468. doi: 10.1016/j.jacc.2023.05.039.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495283/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495283</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.039>10.1016/j.jacc.2023.05.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495283</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan R Salik</dc:creator>
<dc:creator>Emily K Zern</dc:creator>
<dc:creator>Inbar R McCarthy</dc:creator>
<dc:creator>Paul Theriot</dc:creator>
<dc:creator>Kristin West</dc:creator>
<dc:creator>Prashanth Thakker</dc:creator>
<dc:creator>Gaby Weissman</dc:creator>
<dc:creator>Lisa J Rose-Jones</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>In-Person vs Virtual Interview Format for Fellowships in Cardiovascular Disease: A Nationwide Survey of Fellows-in-Training</dc:title>
<dc:identifier>pmid:37495283</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.039</dc:identifier>
</item>
<item>
<title>Mechanisms of Aortic Dilation in Patients With Bicuspid Aortic Valve: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>Bicuspid aortic valve is the most common congenital heart disease and exposes patients to an increased risk of aortic dilation and dissection. Aortic dilation is a slow, silent process, leading to a greater risk of aortic dissection. The prevention of adverse events together with optimization of the frequency of the required lifelong imaging surveillance are important for both clinicians and patients and motivated extensive research to shed light on the physiopathologic processes involved in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):448-464. doi: 10.1016/j.jacc.2022.10.042.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bicuspid aortic valve is the most common congenital heart disease and exposes patients to an increased risk of aortic dilation and dissection. Aortic dilation is a slow, silent process, leading to a greater risk of aortic dissection. The prevention of adverse events together with optimization of the frequency of the required lifelong imaging surveillance are important for both clinicians and patients and motivated extensive research to shed light on the physiopathologic processes involved in bicuspid aortic valve aortopathy. Two main research hypotheses have been consolidated in the last decade: one supports a genetic basis for the increased prevalence of dilation, in particular for the aortic root, and the second supports the damaging impact on the aortic wall of altered flow dynamics associated with these structurally abnormal valves, particularly significant in the ascending aorta. Current opinion tends to rule out mutually excluding causative mechanisms, recognizing both as important and potentially clinically relevant.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495282</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2022.10.042>10.1016/j.jacc.2022.10.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495282</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Jose F Rodríguez-Palomares</dc:creator>
<dc:creator>Lydia Dux-Santoy</dc:creator>
<dc:creator>Andrea Guala</dc:creator>
<dc:creator>Laura Galian-Gay</dc:creator>
<dc:creator>Arturo Evangelista</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mechanisms of Aortic Dilation in Patients With Bicuspid Aortic Valve: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37495282</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2022.10.042</dc:identifier>
</item>
<item>
<title>A Global Challenge and a Global Opportunity for the Heart Failure Community</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495281/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):445-447. doi: 10.1016/j.jacc.2023.05.043.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495281/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495281</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.043>10.1016/j.jacc.2023.05.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495281</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Adam D DeVore</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Global Challenge and a Global Opportunity for the Heart Failure Community</dc:title>
<dc:identifier>pmid:37495281</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.043</dc:identifier>
</item>
<item>
<title>Global Comparison of Readmission Rates for Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Globally, hospitalized HF patients exhibit high rates of readmission and mortality, and the variability in readmission rates was not explained by health care expenditure, risk of mortality, or comorbidities.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):430-444. doi: 10.1016/j.jacc.2023.05.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) readmission rates are low in some jurisdictions. However, international comparisons are lacking and could serve as a foundation for identifying regional patient management strategies that could be shared to improve outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to summarize 30-day and 1-year all-cause readmission and mortality rates of hospitalized HF patients across countries and to explore potential differences in rates globally.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a systematic review and meta-analysis using MEDLINE, Embase, and CENTRAL for observational reports on hospitalized adult HF patients at risk for readmission or mortality published between January 2010 and March 2021. We conducted a meta-analysis of proportions using a random-effects model, and sources of heterogeneity were evaluated with meta-regression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 24 papers reporting on 30-day and 23 papers on 1-year readmission were included. Of the 1.5 million individuals at risk, 13.2% (95% CI: 10.5%-16.1%) were readmitted within 30 days and 35.7% (95% CI: 27.1%-44.9%) within 1 year. A total of 33 papers reported on 30-day and 45 papers on 1-year mortality. Of the 1.5 million individuals hospitalized for HF, 7.6% (95% CI: 6.1%-9.3%) died within 30 days and 23.3% (95% CI: 20.8%-25.9%) died within 1 year. Substantial variation in risk across countries was unexplained by countries' gross domestic product, proportion of gross domestic product spent on health care, and Gini coefficient.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Globally, hospitalized HF patients exhibit high rates of readmission and mortality, and the variability in readmission rates was not explained by health care expenditure, risk of mortality, or comorbidities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495280</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.040>10.1016/j.jacc.2023.05.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495280</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Farid Foroutan</dc:creator>
<dc:creator>Daniel G Rayner</dc:creator>
<dc:creator>Heather J Ross</dc:creator>
<dc:creator>Tamara Ehler</dc:creator>
<dc:creator>Ananya Srivastava</dc:creator>
<dc:creator>Sheojung Shin</dc:creator>
<dc:creator>Abdullah Malik</dc:creator>
<dc:creator>Harsukh Benipal</dc:creator>
<dc:creator>Clarissa Yu</dc:creator>
<dc:creator>Tsz Hin Alexander Lau</dc:creator>
<dc:creator>Joshua G Lee</dc:creator>
<dc:creator>Rodolfo Rocha</dc:creator>
<dc:creator>Peter C Austin</dc:creator>
<dc:creator>Daniel Levy</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>George Tomlinson</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Douglas S Lee</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Global Comparison of Readmission Rates for Patients With Heart Failure</dc:title>
<dc:identifier>pmid:37495280</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.040</dc:identifier>
</item>
<item>
<title>The Evolving Role of C-Reactive Protein in Heart Failure: Implications for Patients With Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495279/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):427-429. doi: 10.1016/j.jacc.2023.05.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495279/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495279</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.036>10.1016/j.jacc.2023.05.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495279</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Ishwarlal Jialal</dc:creator>
<dc:creator>Imo A Ebong</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Evolving Role of C-Reactive Protein in Heart Failure: Implications for Patients With Cardiovascular Disease</dc:title>
<dc:identifier>pmid:37495279</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.036</dc:identifier>
</item>
<item>
<title>C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with established CVD, CRP is an independent risk marker of incident HF. These data support ongoing trial efforts to assess whether anti-inflammatory agents can reduce the burden of HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):414-426. doi: 10.1016/j.jacc.2023.05.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with established cardiovascular disease (CVD) are at high risk of incident heart failure (HF), which may in part reflect the impact of systemic inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to determine the association between C-reactive protein (CRP) and incident HF in patients with established CVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients from the prospective UCC-SMART (Utrecht Cardiovascular Cohort-Second Manifestations of ARTerial disease) cohort with established CVD, but without prevalent HF were included (n = 8,089). Incident HF was defined as a first hospitalization for HF. The association between baseline CRP and incident HF was assessed using Cox proportional hazards models adjusted for established risk factors (ie, age, sex, myocardial infarction, smoking, diabetes mellitus, body mass index, blood pressure, cholesterol, and kidney function).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During a median follow-up of 9.7 years (IQR 5.4-14.1 years), 810 incident HF cases were observed (incidence rate 1.01/100 person-years). Higher CRP was independently associated with an increased risk of incident HF: HR per 1 mg/L: 1.10 (95% CI: 1.07-1.13), and for last vs first CRP quartile: 2.22 (95% CI: 1.76-2.79). The association was significant for both HF with reduced (HR: 1.09; 95% CI: 1.04-1.14) and preserved ejection fraction (HR: 1.12; 95% CI: 1.07-1.18) (P for difference = 0.137). Additional adjustment for medication use and interim myocardial infarction did not attenuate the association, and the association remained consistent beyond 15 years after the CRP measurement.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with established CVD, CRP is an independent risk marker of incident HF. These data support ongoing trial efforts to assess whether anti-inflammatory agents can reduce the burden of HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495278</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.035>10.1016/j.jacc.2023.05.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495278</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Pascal M Burger</dc:creator>
<dc:creator>Stefan Koudstaal</dc:creator>
<dc:creator>Arend Mosterd</dc:creator>
<dc:creator>Aernoud T L Fiolet</dc:creator>
<dc:creator>Martin Teraa</dc:creator>
<dc:creator>Manon G van der Meer</dc:creator>
<dc:creator>Maarten J Cramer</dc:creator>
<dc:creator>Frank L J Visseren</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Jannick A N Dorresteijn</dc:creator>
<dc:creator>UCC-SMART study group</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease</dc:title>
<dc:identifier>pmid:37495278</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.035</dc:identifier>
</item>
<item>
<title>Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal: A Clear Winner?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495277/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):411-413. doi: 10.1016/j.jacc.2023.06.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495277/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495277</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.003>10.1016/j.jacc.2023.06.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495277</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal: A Clear Winner?</dc:title>
<dc:identifier>pmid:37495277</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.003</dc:identifier>
</item>
<item>
<title>Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In clinical practice, combination lipid-lowering therapy with ezetimibe and moderate-intensity statin was associated with favorable clinical outcomes and drug compliance in patients treated with drug-eluting stent implantation. (CONNECT DES Registry; NCT04715594).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):401-410. doi: 10.1016/j.jacc.2023.05.042.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases) trial examined the effects of combination therapy with moderate-intensity statin and ezetimibe in patients with atherosclerotic cardiovascular disease compared with high-intensity statin monotherapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This observational study was conducted to evaluate the impact of 2 treatment strategies used in the RACING trial in clinical practice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: After stabilized inverse probability of treatment weighting, a total of 72,050 patients who were prescribed rosuvastatin after drug-eluting stent implantation were identified from a nationwide cohort database: 10,794 patients with rosuvastatin 10 mg plus ezetimibe 10 mg (combination lipid-lowering therapy) and 61,256 patients with rosuvastatin 20 mg monotherapy. The primary endpoint was the 3-year composite event of cardiovascular death, myocardial infarction, coronary artery revascularization, hospitalization for heart failure treatment, or nonfatal stroke in accordance with the RACING trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Combination lipid-lowering therapy was associated with a lower occurrence of the primary endpoint (11.6% vs 15.2% for those with high-intensity statin monotherapy; HR: 0.75; 95% CI: 0.70-0.79; P &lt; 0.001). Compared with high-intensity statin monotherapy, combination lipid-lowering therapy was associated with fewer discontinuations of statin (6.5% vs 7.6%; HR: 0.85; 95% CI: 0.78-0.94: P &lt; 0.001) and a lower occurrence of new-onset diabetes requiring medication (7.7% vs 9.6%; HR: 0.80; 95% CI: 0.72-0.88; P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In clinical practice, combination lipid-lowering therapy with ezetimibe and moderate-intensity statin was associated with favorable clinical outcomes and drug compliance in patients treated with drug-eluting stent implantation. (CONNECT DES Registry; NCT04715594).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495276</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.042>10.1016/j.jacc.2023.05.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495276</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Seung-Jun Lee</dc:creator>
<dc:creator>Jae Hong Joo</dc:creator>
<dc:creator>Sohee Park</dc:creator>
<dc:creator>Choongki Kim</dc:creator>
<dc:creator>Dong-Woo Choi</dc:creator>
<dc:creator>Sung-Jin Hong</dc:creator>
<dc:creator>Chul-Min Ahn</dc:creator>
<dc:creator>Jung-Sun Kim</dc:creator>
<dc:creator>Byeong-Keuk Kim</dc:creator>
<dc:creator>Young-Guk Ko</dc:creator>
<dc:creator>Donghoon Choi</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Chung-Mo Nam</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention</dc:title>
<dc:identifier>pmid:37495276</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.042</dc:identifier>
</item>
<item>
<title>Long-Term Safety and Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):398-400. doi: 10.1016/j.jacc.2023.05.037.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495275</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.037>10.1016/j.jacc.2023.05.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495275</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan S Steinberg</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Safety and Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator System</dc:title>
<dc:identifier>pmid:37495275</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.037</dc:identifier>
</item>
<item>
<title>Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In the largest prospective study of the S-ICD to date, all study endpoints were met, despite a cohort with more comorbidities than in most previous trials. Complication rates were low and shock efficacy was high. These results demonstrate the 5-year S-ICD safety and efficacy for a large, diverse cohort of S-ICD recipients. (Subcutaneous Implantable Cardioverter-Defibrillator [S-ICD] System Post Approval Study [PAS]; NCT01736618).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 1;82(5):383-397. doi: 10.1016/j.jacc.2023.05.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to avoid complications related to transvenous implantable cardioverter-defibrillator (TV-ICD) leads. Device safety and efficacy were demonstrated previously with atypical clinical patients or limited follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The S-ICD PAS (Subcutaneous Implantable Cardioverter-Defibrillator System Post Approval Study) is a real-world, multicenter, registry of U.S. centers that was designed to assess long-term S-ICD safety and efficacy in a diverse group of patients and implantation centers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were enrolled in 86 U.S. centers with standard S-ICD indications and were observed for up to 5 years. Efficacy endpoints were first and final shock efficacy. Safety endpoints were complications directly related to the S-ICD system or implantation procedure. Endpoints were assessed using prespecified performance goals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,643 patients were prospectively enrolled, with a median follow-up of 4.2 years. All prespecified safety and efficacy endpoint goals were met. Shock efficacy rates for discrete episodes of ventricular tachycardia or ventricular fibrillation were 98.4%, and they did not differ significantly across follow-up years (P = 0.68). S-ICD-related and electrode-related complication-free rates were 93.4% and 99.3%, respectively. Only 1.6% of patients had their devices replaced by a TV-ICD for a pacing need. Cumulative all-cause mortality was 21.7%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the largest prospective study of the S-ICD to date, all study endpoints were met, despite a cohort with more comorbidities than in most previous trials. Complication rates were low and shock efficacy was high. These results demonstrate the 5-year S-ICD safety and efficacy for a large, diverse cohort of S-ICD recipients. (Subcutaneous Implantable Cardioverter-Defibrillator [S-ICD] System Post Approval Study [PAS]; NCT01736618).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495274</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.034>10.1016/j.jacc.2023.05.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495274</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael R Gold</dc:creator>
<dc:creator>Mikhael F El-Chami</dc:creator>
<dc:creator>Martin C Burke</dc:creator>
<dc:creator>Gaurav A Upadhyay</dc:creator>
<dc:creator>Mark J Niebauer</dc:creator>
<dc:creator>Jordan M Prutkin</dc:creator>
<dc:creator>John M Herre</dc:creator>
<dc:creator>Steven Kutalek</dc:creator>
<dc:creator>Jay L Dinerman</dc:creator>
<dc:creator>Bradley P Knight</dc:creator>
<dc:creator>Jill Leigh</dc:creator>
<dc:creator>Lindsay Lucas</dc:creator>
<dc:creator>Nathan Carter</dc:creator>
<dc:creator>Amy J Brisben</dc:creator>
<dc:creator>Johan D Aasbo</dc:creator>
<dc:creator>Raul Weiss</dc:creator>
<dc:creator>S-ICD System Post Approval Study Investigators</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System</dc:title>
<dc:identifier>pmid:37495274</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.034</dc:identifier>
</item>
<item>
<title>Modeling epigenetic lesions that cause gliomas</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>Epigenetic lesions that disrupt regulatory elements represent potential cancer drivers. However, we lack experimental models for validating their tumorigenic impact. Here, we model aberrations arising in isocitrate dehydrogenase-mutant gliomas, which exhibit DNA hypermethylation. We focus on a CTCF insulator near the PDGFRA oncogene that is recurrently disrupted by methylation in these tumors. We demonstrate that disruption of the syntenic insulator in mouse oligodendrocyte progenitor cells...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Jul 20:S0092-8674(23)00729-8. doi: 10.1016/j.cell.2023.06.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epigenetic lesions that disrupt regulatory elements represent potential cancer drivers. However, we lack experimental models for validating their tumorigenic impact. Here, we model aberrations arising in isocitrate dehydrogenase-mutant gliomas, which exhibit DNA hypermethylation. We focus on a CTCF insulator near the PDGFRA oncogene that is recurrently disrupted by methylation in these tumors. We demonstrate that disruption of the syntenic insulator in mouse oligodendrocyte progenitor cells (OPCs) allows an OPC-specific enhancer to contact and induce Pdgfra, thereby increasing proliferation. We show that a second lesion, methylation-dependent silencing of the Cdkn2a tumor suppressor, cooperates with insulator loss in OPCs. Coordinate inactivation of the Pdgfra insulator and Cdkn2a drives gliomagenesis in vivo. Despite locus synteny, the insulator is CpG-rich only in humans, a feature that may confer human glioma risk but complicates mouse modeling. Our study demonstrates the capacity of recurrent epigenetic lesions to drive OPC proliferation in vitro and gliomagenesis in vivo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37494934</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.06.022>10.1016/j.cell.2023.06.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494934</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Gilbert J Rahme</dc:creator>
<dc:creator>Nauman M Javed</dc:creator>
<dc:creator>Kaitlyn L Puorro</dc:creator>
<dc:creator>Shouhui Xin</dc:creator>
<dc:creator>Volker Hovestadt</dc:creator>
<dc:creator>Sarah E Johnstone</dc:creator>
<dc:creator>Bradley E Bernstein</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Modeling epigenetic lesions that cause gliomas</dc:title>
<dc:identifier>pmid:37494934</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.06.022</dc:identifier>
</item>
<item>
<title>Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37495743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Jul 26. doi: 10.1038/s41569-023-00912-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37495743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37495743</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00912-z>10.1038/s41569-023-00912-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37495743</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniel J Piñeiro</dc:creator>
<dc:creator>Elisa Codato</dc:creator>
<dc:creator>Jeremiah Mwangi</dc:creator>
<dc:creator>Jean-Luc Eiselé</dc:creator>
<dc:creator>Jagat Narula</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals</dc:title>
<dc:identifier>pmid:37495743</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00912-z</dc:identifier>
</item>
<item>
<title>Troponins and Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494028/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2109. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494028/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37494028</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2109>10.1001/jamacardio.2023.2109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494028</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Eva Furenäs</dc:creator>
<dc:creator>Mikael Dellborg</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Troponins and Pregnancy</dc:title>
<dc:identifier>pmid:37494028</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2109</dc:identifier>
</item>
<item>
<title>Diversity in Clinical Trial Enrollment and Reporting-Where We Are and the Road Ahead</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2106. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37494022</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2106>10.1001/jamacardio.2023.2106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494022</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew Farb</dc:creator>
<dc:creator>Charles J Viviano</dc:creator>
<dc:creator>Michelle E Tarver</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Diversity in Clinical Trial Enrollment and Reporting-Where We Are and the Road Ahead</dc:title>
<dc:identifier>pmid:37494022</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2106</dc:identifier>
</item>
<item>
<title>Troponins and Pregnancy-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2112. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37494021</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2112>10.1001/jamacardio.2023.2112</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494021</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Anum S Minhas</dc:creator>
<dc:creator>Elizabeth Selvin</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Troponins and Pregnancy-Reply</dc:title>
<dc:identifier>pmid:37494021</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2112</dc:identifier>
</item>
<item>
<title>Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical Trials: A Systematic Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: This review found that over the past 2 decades, women and racial and ethnic minority individuals have remained underrepresented in North American valvular heart disease clinical trials. Further work is needed to improve the reporting of race and ethnicity data and address barriers to trial enrollment for older patients, women, and racial and ethnic minority individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2098. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Inadequate representation of older patients, women, and racial minority individuals in cardiovascular clinical trials limits both the generalizability of trial findings and inclusivity in access to novel therapies and therapeutic strategies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To report on temporal trends in the representation of older patients, women, and racial and ethnic minority individuals in clinical trials studying treatments for valvular heart disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EVIDENCE REVIEW: All published clinical trials enrolling more than 100 adults with any valvular heart disease published between 2005 and 2020 were included after searches with PubMed and ClinicalTrials.gov. Data on age, sex, race, and ethnicity reported in the included studies were collected. Trials were assigned to 4 time periods based on the publication date, and temporal trends were analyzed in the representation of older patients, women, and racial and ethnic minority individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">FINDINGS: A total of 139 clinical trials with 51 527 participants were identified. Of these trials, 103 (74%) investigated aortic valve disease and the remainder mitral valve disease. Overall, 63 trials (45.3%) enrolled patients only in Europe, 24 (17.3%) only in North America, and 19 (13.7%) in multiple geographical regions. The weighted mean (SD) age of enrolled patients was 68.4 (11.4) years, increasing nonsignificantly from 61.9 (5.9) years in 2005-2008 to 72.8 (9.6) years in 2017-2020 (P = .09 for trend). The overall proportion of women enrolled in valvular heart disease trials was 41.1%, with no significant changes over time. Data on race and ethnicity of trial participants were reported in 13 trials (9.4%), in which trial-level representation of American Indian/Alaska Native, Asian, Black/African American, Hispanic, and Native Hawaiian/Pacific Islander patients ranged from 0.27% to 43.9%. There were no significant temporal trends noted in the enrollment of racial and ethnic minority populations. The representation of women in clinical trials was positively associated with enrollment rates of older patients and underrepresented racial and ethnic groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This review found that over the past 2 decades, women and racial and ethnic minority individuals have remained underrepresented in North American valvular heart disease clinical trials. Further work is needed to improve the reporting of race and ethnicity data and address barriers to trial enrollment for older patients, women, and racial and ethnic minority individuals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37494015</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2098>10.1001/jamacardio.2023.2098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494015</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Kriyana P Reddy</dc:creator>
<dc:creator>Michela Faggioni</dc:creator>
<dc:creator>Lauren A Eberly</dc:creator>
<dc:creator>Rim Halaby</dc:creator>
<dc:creator>Monika Sanghavi</dc:creator>
<dc:creator>Jennifer Lewey</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Megan Coylewright</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:creator>Jay Giri</dc:creator>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:creator>Ashwin S Nathan</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical Trials: A Systematic Review</dc:title>
<dc:identifier>pmid:37494015</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2098</dc:identifier>
</item>
<item>
<title>Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37494011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this cross-sectional study, longer LTL was associated with a larger heart with better cardiac function in middle age, which could potentially explain the observed lower risk of incident HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 26. doi: 10.1001/jamacardio.2023.2167. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Longer leukocyte telomere length (LTL) is associated with a lower risk of adverse cardiovascular outcomes. The extent to which variation in LTL is associated with intermediary cardiovascular phenotypes is unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the associations between LTL and a diverse set of cardiovascular imaging phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a population-based cross-sectional study of UK Biobank participants recruited from 2006 to 2010. LTL was measured using a quantitative polymerase chain reaction method. Cardiovascular measurements were derived from cardiovascular magnetic resonance using machine learning. The median (IQR) duration of follow-up was 12.0 (11.3-12.7) years. The associations of LTL with imaging measurements and incident heart failure (HF) were evaluated by multivariable regression models. Genetic associations between LTL and significantly associated traits were investigated by mendelian randomization. Data were analyzed from January to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: LTL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cardiovascular imaging traits and HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 40 459 included participants, 19 529 (48.3%) were men, and the mean (SD) age was 55.1 (7.6) years. Longer LTL was independently associated with a pattern of positive cardiac remodeling (higher left ventricular mass, larger global ventricular size and volume, and higher ventricular and atrial stroke volumes) and a lower risk of incident HF (LTL fourth quartile vs first quartile: hazard ratio, 0.86; 95% CI, 0.81-0.91; P = 1.8 × 10-6). Mendelian randomization analysis suggested a potential causal association between LTL and left ventricular mass, global ventricular volume, and left ventricular stroke volume.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cross-sectional study, longer LTL was associated with a larger heart with better cardiac function in middle age, which could potentially explain the observed lower risk of incident HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37494011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37494011</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2167>10.1001/jamacardio.2023.2167</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37494011</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Nay Aung</dc:creator>
<dc:creator>Qingning Wang</dc:creator>
<dc:creator>Stefan van Duijvenboden</dc:creator>
<dc:creator>Richard Burns</dc:creator>
<dc:creator>Svetlana Stoma</dc:creator>
<dc:creator>Zahra Raisi-Estabragh</dc:creator>
<dc:creator>Selda Ahmet</dc:creator>
<dc:creator>Elias Allara</dc:creator>
<dc:creator>Angela Wood</dc:creator>
<dc:creator>Emanuele Di Angelantonio</dc:creator>
<dc:creator>John Danesh</dc:creator>
<dc:creator>Patricia B Munroe</dc:creator>
<dc:creator>Alistair Young</dc:creator>
<dc:creator>Nicholas C Harvey</dc:creator>
<dc:creator>Veryan Codd</dc:creator>
<dc:creator>Christopher P Nelson</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:creator>Nilesh J Samani</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure</dc:title>
<dc:identifier>pmid:37494011</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2167</dc:identifier>
</item>
<item>
<title>Interaction of Filamin C With Actin Is Essential for Cardiac Development and Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37492967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our data strongly support the crucial role of FLNC as a bridge between actin filaments and ECM through its interactions with actin, ITGB1, γ-SAG, and other associated proteins in cardiomyocytes. Disruption of FLN-actin interaction may result in detachment of actin filaments from the extracellular matrix, ultimately impairing normal cardiac development and function. These findings also provide insights into mechanisms underlying cardiomyopathy associated with genetic variants in FLNC...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 26. doi: 10.1161/CIRCRESAHA.123.322750. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: FLNC (filamin C), a member of the FLN family predominantly expressed in striated muscles, plays a crucial role in bridging the cytoskeleton and ECM (extracellular matrix) in cardiomyocytes, thereby maintaining heart integrity and function. Although genetic variants within the N-terminal ABD (actin-binding domain) of FLNC have been identified in patients with cardiomyopathy, the precise contribution of the actin-binding capability to FLNC's function in mammalian hearts remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted in silico analysis of the 3-dimensional structure of mouse FLNC to identify key amino acid residues within the ABD that are essential for FLNC's actin-binding capacity. Subsequently, we performed coimmunoprecipitation and immunofluorescent assays to validate the in silico findings and assess the impact of these mutations on the interactions with other binding partners and the subcellular localization of FLNC. Additionally, we generated and analyzed knock-in mouse models in which the FLNC-actin interaction was completely disrupted by these mutations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our findings revealed that F93A/L98E mutations completely disrupted FLNC-actin interaction while preserving FLNC's ability to interact with other binding partners ITGB1 (β1 integrin) and γ-SAG (γ-sarcoglycan), as well as maintaining FLNC subcellular localization. Loss of FLNC-actin interaction in embryonic cardiomyocytes resulted in embryonic lethality and cardiac developmental defects, including ventricular wall malformation and reduced cardiomyocyte proliferation. Moreover, disruption of FLNC-actin interaction in adult cardiomyocytes led to severe dilated cardiomyopathy, enhanced lethality and dysregulation of key cytoskeleton components.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data strongly support the crucial role of FLNC as a bridge between actin filaments and ECM through its interactions with actin, ITGB1, γ-SAG, and other associated proteins in cardiomyocytes. Disruption of FLN-actin interaction may result in detachment of actin filaments from the extracellular matrix, ultimately impairing normal cardiac development and function. These findings also provide insights into mechanisms underlying cardiomyopathy associated with genetic variants in FLNC ABD and other regions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37492967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37492967</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322750>10.1161/CIRCRESAHA.123.322750</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37492967</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Xiaohai Zhou</dc:creator>
<dc:creator>Xi Fang</dc:creator>
<dc:creator>Sujay S Ithychanda</dc:creator>
<dc:creator>Tongbin Wu</dc:creator>
<dc:creator>Yusu Gu</dc:creator>
<dc:creator>Chao Chen</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Julius Bogomolovas</dc:creator>
<dc:creator>Jun Qin</dc:creator>
<dc:creator>Ju Chen</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Interaction of Filamin C With Actin Is Essential for Cardiac Development and Function</dc:title>
<dc:identifier>pmid:37492967</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322750</dc:identifier>
</item>
<item>
<title>T-Cell MyD88 Is a Novel Regulator of Cardiac Fibrosis Through Modulation of T-Cell Activation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37492941/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our results outline a novel intrinsic role for MyD88 in limiting T-cell activation that is central to tune down cardiac inflammation during cardiac adaptation to stress.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 26. doi: 10.1161/CIRCRESAHA.123.323030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac inflammation in heart failure is characterized by the presence of damage-associated molecular patterns, myeloid cells, and T cells. Cardiac damage-associated molecular patterns provide continuous proinflammatory signals to myeloid cells through TLRs (toll-like receptors) that converge onto the adaptor protein MyD88 (myeloid differentiation response 88). These induce activation into efficient antigen-presenting cells that activate T cells through their TCR (T-cell receptor). T-cell activation results in cardiotropism, cardiac fibroblast transformation, and maladaptive cardiac remodeling. T cells rely on TCR signaling for effector function and survival, and while they express MyD88 and damage-associated molecular pattern receptors, their role in T-cell activation and cardiac inflammation is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed transverse aortic constriction in mice lacking MyD88 in T cells and analyzed remodeling, systolic function, survival, and T-cell activation. We profiled WT versus <i>Myd88</i><sup><i>-/-</i></sup> mouse T cells at the transcript and protein level and performed several functional assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Analysis of single-cell RNA-sequencing data sets revealed that MyD88 is expressed in mouse and human cardiac T cells. MyD88 deletion in T cells resulted in increased levels of cardiac T-cell infiltration and fibrosis in response to transverse aortic constriction. We discovered that TCR-activated <i>Myd88</i><sup><i>-/-</i></sup> T cells had increased proinflammatory signaling at the transcript and protein level compared with WT, resulting in increased T-cell effector functions such as adhesion, migration across endothelial cells, and activation of cardiac fibroblast. Mechanistically, we found that MyD88 modulates T-cell activation and survival through TCR-dependent rather than TLR-dependent signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results outline a novel intrinsic role for MyD88 in limiting T-cell activation that is central to tune down cardiac inflammation during cardiac adaptation to stress.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37492941/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37492941</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323030>10.1161/CIRCRESAHA.123.323030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37492941</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Abraham L Bayer</dc:creator>
<dc:creator>Sasha Smolgovsky</dc:creator>
<dc:creator>Njabulo Ngwenyama</dc:creator>
<dc:creator>Ana Hernández-Martínez</dc:creator>
<dc:creator>Kuljeet Kaur</dc:creator>
<dc:creator>Katherine Sulka</dc:creator>
<dc:creator>Junedh Amrute</dc:creator>
<dc:creator>Mark Aronovitz</dc:creator>
<dc:creator>Kory Lavine</dc:creator>
<dc:creator>Shruti Sharma</dc:creator>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>T-Cell MyD88 Is a Novel Regulator of Cardiac Fibrosis Through Modulation of T-Cell Activation</dc:title>
<dc:identifier>pmid:37492941</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323030</dc:identifier>
</item>
<item>
<title>Unravelling ACS pathophysiology using intracoronary OCT and deep immunophenotyping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37491589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230727062803&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Jul 25. doi: 10.1038/s41569-023-00915-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37491589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230727062803&v=2.17.9.post6+86293ac">37491589</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00915-w>10.1038/s41569-023-00915-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37491589</guid>
<pubDate>Wed, 26 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Harman</dc:creator>
<dc:date>2023-07-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Unravelling ACS pathophysiology using intracoronary OCT and deep immunophenotyping</dc:title>
<dc:identifier>pmid:37491589</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00915-w</dc:identifier>
</item>





























</channel>
</rss>